TAF15

Across TCGA pan-cancer cohorts, TAF15 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAF15 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TAF15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF15 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUAD, UCEC, and DLBC are the cancer types where TAF15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.211	0.790	<.001	29	view →
UCEC	DFS	Median	All	1.000	0.625	.002	22	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
LIHC	DFS	Median	All	0.106	0.553	.047	3	view →
BLCA	OS	Median	III,IV	1.000	0.353	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAF15–LUAD (OS)

Open the LUAD breakdown →